<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6008231 - Antiallergens, antihistamines, immunosuppressants, immunomodulators - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Antiallergens, antihistamines, immunosuppressants, immunomodulators"><meta name="DC.contributor" content="Guillaume Lebaut" scheme="inventor"><meta name="DC.contributor" content="Cecilia Menciu" scheme="inventor"><meta name="DC.contributor" content="Bernhard Kutscher" scheme="inventor"><meta name="DC.contributor" content="Peter Emig" scheme="inventor"><meta name="DC.contributor" content="Stefan Szelenyi" scheme="inventor"><meta name="DC.contributor" content="Kay Brune" scheme="inventor"><meta name="DC.contributor" content="Asta Medica Aktiengesellschgt" scheme="assignee"><meta name="DC.date" content="1997-9-8" scheme="dateSubmitted"><meta name="DC.description" content="The invention relates to novel N-substituted indole-3-glyoxylamides, to processes for their preparation and to their pharmaceutical use. The compounds have antiasthmatic, antiallergic and immuno-suppressant/immunomodulating actions."><meta name="DC.date" content="1999-12-28" scheme="issued"><meta name="DC.relation" content="EP:0675110:A1" scheme="references"><meta name="DC.relation" content="US:3135794" scheme="references"><meta name="DC.relation" content="US:3801594" scheme="references"><meta name="citation_reference" content="Archibald et al., &quot;1,4-Bis(2-indol-3-ylethyl)piperazines,&quot; J. Med. Chem., vol. 17, No. 7, pp. 745-747, 1974."><meta name="citation_reference" content="Archibald et al., 1,4 Bis(2 indol 3 ylethyl)piperazines, J. Med. Chem., vol. 17, No. 7, pp. 745 747, 1974."><meta name="citation_reference" content="Chem. Abstr. 115007v American Home Products, &quot;Therapeutic bis(indolyl) compounds,&quot; vol. 70, p. 15007, 1969."><meta name="citation_reference" content="Chem. Abstr. 115007v American Home Products, Therapeutic bis(indolyl) compounds, vol. 70, p. 15007, 1969."><meta name="citation_reference" content="Chem. Abstr. 120:125105r Evans et al., &quot;Probing the 5-HT3 receptor site using novel indole-3-glyoxylic acid derivatves,&quot; vol. 120, p. 123, 1994."><meta name="citation_reference" content="Chem. Abstr. 120:125105r Evans et al., Probing the 5 HT3 receptor site using novel indole 3 glyoxylic acid derivatves, vol. 120, p. 123, 1994."><meta name="citation_reference" content="Chem. Abstr. 37598x Podwinski, &quot;Synthesis of some 5-benzyloxyindole-3-glyoxylic acid amides,&quot; vol. 70, p. 327, 1969."><meta name="citation_reference" content="Chem. Abstr. 37598x Podwinski, Synthesis of some 5 benzyloxyindole 3 glyoxylic acid amides, vol. 70, p. 327, 1969."><meta name="citation_reference" content="Chem. Abstr. 3871 P eng et al., Synthesis of derivatives of 5,6 disubstituted 3 (Beta aminoethyl) indole, vol. 65, 1966."><meta name="citation_reference" content="Chem. Abstr. 3871 P&#39;eng et al., &quot;Synthesis of derivatives of 5,6-disubstituted 3-(Beta-aminoethyl)-indole,&quot; vol. 65, 1966."><meta name="citation_reference" content="Chem. Abstr. 53968m Bertaccini et al., &quot;Synthesis and Pharmacological activity of some 5-methoxyindole derivatives occurring in nature,&quot; vol. 67, p. 5069, 1967."><meta name="citation_reference" content="Chem. Abstr. 53968m Bertaccini et al., Synthesis and Pharmacological activity of some 5 methoxyindole derivatives occurring in nature, vol. 67, p. 5069, 1967."><meta name="citation_reference" content="Chem. Abstr. 86: 106379w Alvarez et al., &quot;3-(2-Aminoethyl)indole derivatives,&quot; vol. 86, p. 491, 1977."><meta name="citation_reference" content="Chem. Abstr. 86: 106379w Alvarez et al., 3 (2 Aminoethyl)indole derivatives, vol. 86, p. 491, 1977."><meta name="citation_reference" content="Chem. Abstr. 87491p Brewster et al., &quot;Antihypertensive 1,4-bis(2-indol-3-ylethyl)piperazines,&quot; vol. 79, p. 27, 1973."><meta name="citation_reference" content="Chem. Abstr. 87491p Brewster et al., Antihypertensive 1,4 bis(2 indol 3 ylethyl)piperazines, vol. 79, p. 27, 1973."><meta name="citation_reference" content="Chem. Abstr. 92: 128647h. CXIV. Eryshev et al., &quot;Synthesis of anilides of indolylalkanoic acids,&quot; vol. 92, p. 673, 1980."><meta name="citation_reference" content="Chem. Abstr. 92: 128647h. CXIV. Eryshev et al., Synthesis of anilides of indolylalkanoic acids, vol. 92, p. 673, 1980."><meta name="citation_reference" content="Chem. Abstr. 9293 Sterling Drug Inc., &quot;Indolylpiperazines,&quot; vol. 60, 1964."><meta name="citation_reference" content="Chem. Abstr. 9293 Sterling Drug Inc., Indolylpiperazines, vol. 60, 1964."><meta name="citation_reference" content="Domschke et al., &quot;Notiz zur Darstellung einiger [1-Benzyl-2-methyl-5-methoxy-indolyl-(3)]-glyoxylsaureamide,&quot; vol. 94, pp. 2353-2355, 1961."><meta name="citation_reference" content="Domschke et al., Notiz zur Darstellung einiger 1 Benzyl 2 methyl 5 methoxy indolyl (3) glyoxylsaureamide, vol. 94, pp. 2353 2355, 1961."><meta name="citation_reference" content="Evans et al., &quot;Probing the 5-HT3 receptor site using novel indole-3-glyoxylic acid derivatives,&quot; Med. Chem. Res., 3(5-6), pp. 386-406, 1993."><meta name="citation_reference" content="Evans et al., Probing the 5 HT3 receptor site using novel indole 3 glyoxylic acid derivatives, Med. Chem. Res., 3(5 6), pp. 386 406, 1993."><meta name="citation_reference" content="Glamkowski et al., &quot;Synthesis of 3-(4-Acylaminopiperazin-1-ylalkyl)indoles as Potential Antihypertensive Agents,&quot; J. Med. Chem., vol. 20, No. 11, pp. 148-152, 1977."><meta name="citation_reference" content="Glamkowski et al., Synthesis of 3 (4 Acylaminopiperazin 1 ylalkyl)indoles as Potential Antihypertensive Agents, J. Med. Chem., vol. 20, No. 11, pp. 148 152, 1977."><meta name="citation_reference" content="Lipp et al., &quot;Notiz uber einige Derivate der [5-Benzyloxy-indolyl-(3)]-glyoxylsaure,&quot; Chem. Ber., vol. 91, pp. 242-243, 1957."><meta name="citation_reference" content="Lipp et al., Notiz uber einige Derivate der 5 Benzyloxy indolyl (3) glyoxylsaure, Chem. Ber., vol. 91, pp. 242 243, 1957."><meta name="citation_patent_number" content="US:6008231"><meta name="citation_patent_application_number" content="US:08/925,326"><link rel="canonical" href="http://www.google.com/patents/US6008231"/><meta property="og:url" content="http://www.google.com/patents/US6008231"/><meta name="title" content="Patent US6008231 - Antiallergens, antihistamines, immunosuppressants, immunomodulators"/><meta name="description" content="The invention relates to novel N-substituted indole-3-glyoxylamides, to processes for their preparation and to their pharmaceutical use. The compounds have antiasthmatic, antiallergic and immuno-suppressant/immunomodulating actions."/><meta property="og:title" content="Patent US6008231 - Antiallergens, antihistamines, immunosuppressants, immunomodulators"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("X6PtU4qiKsrtoATm2oLoDA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("NZL"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("X6PtU4qiKsrtoATm2oLoDA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("NZL"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6008231?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6008231"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=JJJNBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6008231&amp;usg=AFQjCNEKx78568fjZ804EeeDPjNWqH4HaQ" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6008231.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6008231.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6008231" style="display:none"><span itemprop="description">The invention relates to novel N-substituted indole-3-glyoxylamides, to processes for their preparation and to their pharmaceutical use. The compounds have antiasthmatic, antiallergic and immuno-suppressant/immunomodulating actions....</span><span itemprop="url">http://www.google.com/patents/US6008231?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6008231 - Antiallergens, antihistamines, immunosuppressants, immunomodulators</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6008231 - Antiallergens, antihistamines, immunosuppressants, immunomodulators" title="Patent US6008231 - Antiallergens, antihistamines, immunosuppressants, immunomodulators"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6008231 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/925,326</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Dec 28, 1999</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Sep 8, 1997</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Sep 6, 1996</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2215013A1">CA2215013A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2215013C">CA2215013C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1227542A">CN1227542A</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1496980A">CN1496980A</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN100376554C">CN100376554C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN100488948C">CN100488948C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN101219985A">CN101219985A</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN101219985B">CN101219985B</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE19636150A1">DE19636150A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE59712752D1">DE59712752D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0931063A1">EP0931063A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0931063B1">EP0931063B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0931063B3">EP0931063B3</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6344467">US6344467</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6919344">US6919344</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20020161025">US20020161025</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20030207892">US20030207892</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1998009946A1">WO1998009946A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08925326, </span><span class="patent-bibdata-value">925326, </span><span class="patent-bibdata-value">US 6008231 A, </span><span class="patent-bibdata-value">US 6008231A, </span><span class="patent-bibdata-value">US-A-6008231, </span><span class="patent-bibdata-value">US6008231 A, </span><span class="patent-bibdata-value">US6008231A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Guillaume+Lebaut%22">Guillaume Lebaut</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Cecilia+Menciu%22">Cecilia Menciu</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Bernhard+Kutscher%22">Bernhard Kutscher</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Peter+Emig%22">Peter Emig</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Stefan+Szelenyi%22">Stefan Szelenyi</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Kay+Brune%22">Kay Brune</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Asta+Medica+Aktiengesellschgt%22">Asta Medica Aktiengesellschgt</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6008231.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6008231.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6008231.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (3),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (28),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (35),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (41),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (9)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6008231&usg=AFQjCNGO7K97XwL_DY-i1waQjElVC334Uw">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6008231&usg=AFQjCNECDT7ihhRnIu3sUiBMteR3D6UDMQ">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6008231A%26KC%3DA%26FT%3DD&usg=AFQjCNHJCbEDA9qirWEqDPX7zce_O2WXpg">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT129011079" lang="EN" load-source="ifi">Antiallergens, antihistamines, immunosuppressants, immunomodulators</invention-title></span><br><span class="patent-number">US 6008231 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA38015146" lang="EN" load-source="patent-office"> <div class="abstract">The invention relates to novel N-substituted indole-3-glyoxylamides, to processes for their preparation and to their pharmaceutical use. The compounds have antiasthmatic, antiallergic and immuno-suppressant/immunomodulating actions.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(23)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-14.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-14.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-15.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-15.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-16.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-16.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-17.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-17.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-18.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-18.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-19.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-19.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-20.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-20.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-21.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-21.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6008231-22.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6008231-22.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(11)</span></span></div><div class="patent-text"><div mxw-id="PCLM59537966" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. An N-substituted indol- 3-glyoxylamide of formula I: ##STR65## or an acid addition salt thereof, wherein the radicals R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and Z have the following meanings:<div class="claim-text">R represents<div class="claim-text">(1) hydrogen, or</div> <div class="claim-text">(2) (C<sub>1</sub> -C<sub>4</sub>)-alkyl, wherein the alkyl group is optionally mono- or polysubstituted by a phenyl ring,<div class="claim-text">which ring is optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carbonyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, benzyloxy groups and benzyl groups which are optionally mono- or polysubstituted on the phenyl moiety by (C<sub>1</sub> -C<sub>6</sub>)alkyl groups, halogen atoms or trifluoromethyl groups;</div> </div> </div> <div class="claim-text">R<sub>1</sub> represents<div class="claim-text">(1) a phenyl ring which is mono- or polysubstituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, hydroxyl, benzyloxy, nitro, amino, (C<sub>1</sub> -C<sub>6</sub>)-alkylamino, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy-carbonylamino and by a carboxyl group or a carboxyl group esterified by a (C<sub>1</sub> -C<sub>6</sub>)-alkanol;</div> <div class="claim-text">(2) a pyridine structure of formula II: ##STR66##  wherein the pyridine structure is alternatively bonded to the ring carbon atoms 2, 3 and 4 and is optionally substituted by R<sub>5</sub> and R<sub>6</sub>, which may be identical or different and represent (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>) cycloalkyl, (C<sub>1</sub> -C<sub>6</sub>)alkoxy, nitro, amino, hydroxyl, halogen, trifluromethyl, an ethoxycarbonylamino radical and a carboxyalkyloxy group in which the alkyl group has 1-4 carbon atoms;</div> <div class="claim-text">(3) a pyridylmethyl radical in which CH<sub>2</sub> is in the 2-, 3- or 4-position;</div> <div class="claim-text">(4) a 2-, 3- or 4-quinolyl structure substituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, halogen, a nitro group, an amino group or a (C<sub>1</sub> -C<sub>6</sub>)-alkylamino radical;</div> <div class="claim-text">(5) a 2-, 3- or 4-quinolyl methyl group, wherein the ring carbons of the pyridylmethyl and quinolylmethyl radicals are optionally substituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, nitro, amino and (C<sub>1</sub> -C<sub>6</sub>)-alkoxy-carbonylamino;</div> <div class="claim-text">(6) if R represents hydrogen or a benzyl group, R<sub>1</sub> can represent the acid radical of a natural amino acid, wherein the amino group of said amino acid is present in protected or unprotected form wherein if R<sub>1</sub> represents an asparagyl or a glutamyl radical having a second nonbonded carboxyl group, said nonbonded carboxyl group is present as a free carboxyl group or in the form of an ester with C<sub>1</sub> -C<sub>6</sub> -alkanols;</div> <div class="claim-text">(7) an allylaminocarbonyl-2-methylprop-1-yl group;</div> </div> <div class="claim-text">R<sub>2</sub> represents<div class="claim-text">(1) hydrogen;</div> <div class="claim-text">(2) a (C<sub>1</sub> -C<sub>6</sub>)-alkyl group,<div class="claim-text">said alkyl group being optionally mono- or polysubstituted by halogen or a phenyl ring,<div class="claim-text">which ring is optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carbonyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, or benzyloxy groups;</div> </div> <div class="claim-text">or by a 2-quinolyl group or a 2-, 3- or 4-pyridyl structure which are optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>4</sub>)-alkyl groups or (C<sub>1</sub> -C<sub>4</sub>)-alkoxy groups;</div> </div> <div class="claim-text">(3) an aroyl radical, wherein the aroyl moiety on which the radical is based is a phenyl ring which is optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carbonyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, or benzyloxy groups;</div> </div> <div class="claim-text">R<sub>3</sub> and R<sub>4</sub>, which are identical or different, represent hydrogen, hydroxyl, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkanoyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, halogen, benzoxy, a nitro group, an amino group, a (C<sub>1</sub> -C<sub>4</sub>)-mono- or dialkyl substituted amino group, a (C<sub>1</sub> -C<sub>3</sub>)-alkoxycarbonylamino function or a (C<sub>1</sub> -C<sub>3</sub>)-alkoxycarbonylamino-(C<sub>1</sub> -C<sub>3</sub>)-alkyl function; and</div> <div class="claim-text">Z represents O or S;<div class="claim-text">wherein alkyl, alkanol, alkoxy and alkylamino groups may be straight chained or branched.</div> </div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The N-substituted indol-3-glyoxylamide of claim 1 wherein R is hydrogen or a benzyl group and R<sub>1</sub> is the acid radical of an amino acid selected from the group consisting of α-glycyl, α-alanyl, α-leucyl, α-isoleucyl, α-seryl, α-phenylalanyl, α-arginyl, α-lysyl, α-asparagyl and α-glutamyl.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. A compound according to claim 1 selected from the group consisting of:<div class="claim-text">N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl)-(4-methylindol-3-yl)glyoxylamide</div> <div class="claim-text">N-(Pyridin-3-yl)-[1-(4-fluorobenzyl)-indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-3-yl)-(1-benzylindol-3-yl)glyoxylamide</div> <div class="claim-text">N-(Pyridin-3-yl)-[1-(2-chorobenzyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(4-Fluorophenyl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(4-Nitrophenyl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(2-Chloropyridine-3-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl)-(-benzylindol-3-yl)glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl)-[1-(3-pyridylmethyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(4-Fluorophenyl)-[1-(2-pyridylmethyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(4-Fluorophenyl)-[1-(3-pyridylmethyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl)-[1-(2-chlorobenzyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-2-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl)-[1-(2-pyridylmethyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-2-yl)-(1-benzylindol-3-yl)glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)-6-ethoxycarbonylaminoindol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)-5-ethoxycarbonylaminoindol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-)-[1-(4-fluorobenzyl)-6-cyclopentyloxycarbonylaminoindol-3-yl]glyoxylamide</div> <div class="claim-text">N-(3,4,5-Trimethoxybenzyl)-N-(allylaminocarbonyl-2-methylprop-1-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)-5-methoxyindol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide</div> <div class="claim-text">N-(Pyridin-4-yl-[1-(4-fluorobenzyl)-5-ethoxycarbonylaminomethylindol-3-yl]glyoxylamide.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. Medicaments comprising at least one compound of the formula I according to one of claims 1 or 3 in addition to customary excipients and/or diluents or auxiliaries.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. Process for the production of a medicament, wherein a compound of the formula I according to one of claims 1 or 3 is processed with customary pharmaceutical excipients and/or diluents or other auxiliaries to give pharmaceutical preparations or brought into a therapeutically useable form.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. Medicaments according to one of claims 1 or 3 in the form of tablets, coated tablets, capsules, solutions or ampoules, suppositories, patches, powder preparations which can be employed by inhalation, suspensions, creams and ointments.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. Process for the preparation of N-substituted indole-3-glyoxylamides of the formula I according to claims 1 and 3, in which R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and Z have the meaning mentioned in claim 1, wherein<div class="claim-text">a) an indole derivative of the formula IV ##STR67## in which R<sub>3</sub> and R<sub>4</sub> have the meaning mentioned, is added to a suspended base in a protic, dipolar aprotic or nonpolar organic solvent, reacted with a reactive compound which carries the radical R<sub>2</sub> and where R<sub>2</sub> has the meaning mentioned, the 1-indole derivative of the formula V ##STR68## in which R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> have the meaning mentioned, is reacted with a reactive compound of the formula VI<div class="claim-text"> <pre xml:space="preserve" listing-type="equation">(C--Z--Hal)<sub>2</sub>                                          VI</pre> </div> <div class="claim-text">in which Z has the meaning oxygen and Hal is a halogen fluorine, chlorine, bromine or iodine, and then with a primary or secondary amine of the formula VII</div> <div class="claim-text"> <pre xml:space="preserve" listing-type="equation">HNRR<sub>1</sub>                                                 VII</pre> </div> <div class="claim-text">in which R and R<sub>1</sub> have the meaning mentioned, in an aprotic or dipolar aprotic solvent and the target compound of the formula I is isolated, or</div> </div> <div class="claim-text">b) an indole derivative of the formula IV ##STR69## in which R<sub>3</sub> and R<sub>4</sub> have the meaning mentioned, is reacted in an aprotic or nonpolar solvent with a reactive compound of the formula VI<div class="claim-text"> <pre xml:space="preserve" listing-type="equation">(C--Z--Hal)<sub>2</sub>                                          VI</pre> </div> <div class="claim-text">in which Z has the meaning oxygen and Hal is a halogen fluorine, chlorine, bromine or iodine, and then in an aprotic or dipolar aprotic solvent with a primary or secondary amine of the formula VII</div> <div class="claim-text"> <pre xml:space="preserve" listing-type="equation">HNRR<sub>1</sub>                                                 VII</pre> </div> <div class="claim-text">in which R and R<sub>1</sub> have the meaning mentioned, and then the 3-indole derivative of the formula VIII ##STR70## in which R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and Z have the meaning mentioned, is reacted in a protic, dipolar aprotic or nonpolar organic solvent in the presence of a suspended base with a reactive compound which carries the radical R<sub>2</sub> and where R<sub>2</sub> has the meaning mentioned, and the target compound of the formula I is isolated.</div> </div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. The N-substituted indol-3-glyoxylamide of claim 2 wherein R represents hydrogen or a benzyl group and R<sub>1</sub> represents α-asparagyl or α-glutamyl, in which the nonbonded carboxyl group is a methyl, ethyl or tert-butyl ester.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. The N-substituted indol-3-glyoxylamide of claim 2 wherein R represents hydrogen or a benzyl group and R<sub>1</sub> represents the acid radical of a natural amino acid protected by a carbobenzoxy radical, a tert-butoxycarbonyl radical or an acetyl group.</div>
    </div>
    </div> <div class="claim"> <div num="10" class="claim">
      <div class="claim-text">10. A method of treating asthma and/or allergy in a mammal comprising the step of administering to said mammal a treatment-effective amount of a compound of formula I: ##STR71## or an acid addition salt thereof, wherein the radicals R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and Z have the following meanings:<div class="claim-text">R represents<div class="claim-text">(1) hydrogen, or</div> <div class="claim-text">(2) (C<sub>1</sub> -C<sub>4</sub>)-alkyl, wherein the alkyl group is optionally mono- or polysubstituted by a phenyl ring,<div class="claim-text">which ring is optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carbonyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, benzyloxy groups and benzyl groups which are optionally mono- or polysubstituted on the phenyl moiety by (C<sub>1</sub> -C<sub>6</sub>)alkyl groups, halogen atoms or trifluoromethyl groups;</div> </div> </div> <div class="claim-text">R<sub>1</sub> represents<div class="claim-text">(1) a phenyl ring which is mono- or polysubstituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, hydroxyl, benzyloxy, nitro, amino, (C<sub>1</sub> -C<sub>6</sub>)-alkylamino, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy-carbonylamino and by a carboxyl group or a carboxyl group esterified by a (C<sub>1</sub> -C<sub>6</sub>)-alkanol;</div> <div class="claim-text">(2) a pyridine structure of formula II: ##STR72##  wherein the pyridine structure is alternatively bonded to the ring carbon atoms 2, 3 and 4 and is optionally substituted by R<sub>5</sub> and R<sub>6</sub>, which may be identical or different and represent (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>) cycloalkyl, (C<sub>1</sub> -C<sub>6</sub>)alkoxy, nitro, amino, hydroxyl, halogen, trifluromethyl, an ethoxycarbonylamino radical and a carboxyalkyloxy group in which the alkyl group has 1-4 carbon atoms;</div> <div class="claim-text">(3) a pyridylmethyl radical in which CH<sub>2</sub> is in the 2-, 3- or 4-position;</div> <div class="claim-text">(4) a 2-, 3- or 4-quinolyl structure substituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, halogen, a nitro group, an amino group or a (C<sub>1</sub> -C<sub>6</sub>)-alkylamino radical;</div> <div class="claim-text">(5) a 2-, 3- or 4-quinolyl methyl group, wherein the ring carbons of the pyridylmethyl and quinolylmethyl radicals are optionally substituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, nitro, amino and (C<sub>1</sub> -C<sub>6</sub>)-alkoxy-carbonylamino;</div> <div class="claim-text">(6) if R represents hydrogen or a benzyl group, R<sub>1</sub> can represent the acid radical of a natural amino acid, wherein the amino group of said amino acid is present in protected or unprotected form wherein if R<sub>1</sub> represents an asparagyl or a glutamyl radical having a second nonbonded carboxyl group, said nonbonded carboxyl group is present as a free carboxyl group or in the form of an ester with C<sub>1</sub> -C<sub>6</sub> -alkanols;</div> <div class="claim-text">(7) an allylaminocarbonyl-2-methylprop-1-yl group;</div> </div> <div class="claim-text">R<sub>2</sub> represents<div class="claim-text">(1) hydrogen;</div> <div class="claim-text">(2) a (C<sub>1</sub> -C<sub>6</sub>)-alkyl group,<div class="claim-text">said alkyl group being optionally mono- or polysubstituted by halogen or a phenyl ring,<div class="claim-text">which ring is optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carbonyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, or benzyloxy groups;</div> </div> <div class="claim-text">or by a 2-quinolyl group or a 2-, 3- or 4-pyridyl structure which are optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>4</sub>)-alkyl groups or (C<sub>1</sub> -C<sub>4</sub>)-alkoxy groups;</div> </div> <div class="claim-text">(3) an aroyl radical, wherein the aroyl moiety on which the radical is based is a phenyl ring which is optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carbonyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, or benzyloxy groups;</div> </div> <div class="claim-text">R<sub>3</sub> and R<sub>4</sub>, which are identical or different, represent hydrogen, hydroxyl, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkanoyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, halogen, benzoxy, a nitro group, an amino group, a (C<sub>1</sub> -C<sub>4</sub>)-mono- or dialkyl substituted amino group, a (C<sub>1</sub> -C<sub>3</sub>)-alkoxycarbonylamino function or a (C<sub>1</sub> -C<sub>3</sub>)-alkoxycarbonylamino-(C<sub>1</sub> -C<sub>3</sub>)-alkyl function; and</div> <div class="claim-text">Z represents O or S;<div class="claim-text">wherein alkyl, alkanol, alkoxy and alkylamino groups may be straight chained or branched.</div> </div> </div>
    </div>
    </div> <div class="claim"> <div num="11" class="claim">
      <div class="claim-text">11. A method of inducing regression of an immunological reaction in a mammal comprising the step of administering to said mammal an effective amount of a compound according to formula I: ##STR73## or an acid addition salt thereof, wherein the radicals R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and Z have the following meanings:<div class="claim-text">R represents<div class="claim-text">(1) hydrogen, or</div> <div class="claim-text">(2) (C<sub>1</sub> -C<sub>4</sub>)-alkyl, wherein the alkyl group is optionally mono- or polysubstituted by a phenyl ring,<div class="claim-text">which ring is optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carbonyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, benzyloxy groups and benzyl groups which are optionally mono- or polysubstituted on the phenyl moiety by (C<sub>1</sub> -C<sub>6</sub>)alkyl groups, halogen atoms or trifluoromethyl groups;</div> </div> </div> <div class="claim-text">R<sub>1</sub> represents<div class="claim-text">(1) a phenyl ring which is mono- or polysubstituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, hydroxyl, benzyloxy, nitro, amino, (C<sub>1</sub> -C<sub>6</sub>)-alkylamino, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy-carbonylamino and by a carboxyl group or a carboxyl group esterified by a (C<sub>1</sub> -C<sub>6</sub>)-alkanol;</div> <div class="claim-text">(2) a pyridine structure of formula II: ##STR74##  wherein the pyridine structure is alternatively bonded to the ring carbon atoms 2, 3 and 4 and is optionally substituted by R<sub>5</sub> and R<sub>6</sub>, which may be identical or different and represent (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>) cycloalkyl, (C<sub>1</sub> -C<sub>6</sub>)alkoxy, nitro, amino, hydroxyl, halogen, trifluromethyl, an ethoxycarbonylamino radical and a carboxyalkyloxy group in which the alkyl group has 1-4 carbon atoms;</div> <div class="claim-text">(3) a pyridylmethyl radical in which CH<sub>2</sub> is in the 2-, 3- or 4-position;</div> <div class="claim-text">(4) a 2-, 3- or 4-quinolyl structure substituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, halogen, a nitro group, an amino group or a (C<sub>1</sub> -C<sub>6</sub>)-alkylamino radical;</div> <div class="claim-text">(5) a 2-, 3- or 4-quinolyl methyl group, wherein the ring carbons of the pyridylmethyl and quinolylmethyl radicals are optionally substituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, nitro, amino and (C<sub>1</sub> -C<sub>6</sub>)-alkoxy-carbonylamino;</div> <div class="claim-text">(6) if R represents hydrogen or a benzyl group, R<sub>1</sub> can represent the acid radical of a natural amino acid, wherein the amino group of said amino acid is present in protected or unprotected form wherein if R<sub>1</sub> represents an asparagyl or a glutamyl radical having a second nonbonded carboxyl group, said nonbonded carboxyl group is present as a free carboxyl group or in the form of an ester with C<sub>1</sub> -C<sub>6</sub> -alkanols;</div> <div class="claim-text">(7) an allylaminocarbonyl-2-methylprop-1-yl group;</div> </div> <div class="claim-text">R<sub>2</sub> represents<div class="claim-text">(1) hydrogen;</div> <div class="claim-text">(2) a (C<sub>1</sub> -C<sub>6</sub>)-alkyl group,<div class="claim-text">said alkyl group being optionally mono- or polysubstituted by halogen or a phenyl ring,<div class="claim-text">which ring is optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carbonyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, or benzyloxy groups;</div> </div> <div class="claim-text">or by a 2-quinolyl group or a 2-, 3- or 4-pyridyl structure which are optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>4</sub>)-alkyl groups or (C<sub>1</sub> -C<sub>4</sub>)-alkoxy groups;</div> </div> <div class="claim-text">(3) an aroyl radical, wherein the aroyl moiety on which the radical is based is a phenyl ring which is optionally mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carbonyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, or benzyloxy groups;</div> </div> <div class="claim-text">R<sub>3</sub> and R<sub>4</sub>, which are identical or different, represent hydrogen, hydroxyl, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkanoyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, halogen, benzoxy, a nitro group, an amino group, a (C<sub>1</sub> -C<sub>4</sub>)-mono- or dialkyl substituted amino group, a (C<sub>1</sub> -C<sub>3</sub>)-alkoxycarbonylamino function or a (C<sub>1</sub> -C<sub>3</sub>)-alkoxycarbonylamino-(C<sub>1</sub> -C<sub>3</sub>)-alkyl function; and</div> <div class="claim-text">Z represents O or S;<div class="claim-text">wherein alkyl, alkanol, alkoxy and alkylamino groups may be straight chained or branched.</div> </div> </div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67394961" lang="EN" load-source="patent-office" class="description">
    <heading>BACKGROUND OF THE INVENTION</heading> <p>1. Field of the Invention</p>
    <p>The invention relates to novel N-substituted indole-3-glyoxylamides, processes for their preparation and pharmaceutical uses. The compounds have antiasthmatic, antiallergic and immunosuppressant/immunomodulating properties.</p>
    <p>2. Background Information</p>
    <p>Indole-3-glyoxylamides have various uses as pharmaco-dynamically active compounds and as synthesis components in the pharmaceutical chemistry.</p>
    <p>The Patent Application NL 6502481 describes compounds which have an antiinflammatory and antipyretic profile of action and analgesic activity.</p>
    <p>The British Patent GB 1 028 812 mentions derivatives of indolyl-3-glyoxylic acid and its amides as compounds having analgesic, anticonvulsant and β-adrenergic activity.</p>
    <p>G. Domschke et al. (Ber. 94, 2353 (1961)) describe 3-indolylglyoxylamides which are not characterized pharmacologically.</p>
    <p>E. Walton et al. in J. Med. Chem. 11,1252 (1968) report on indolyl-3-glyoxylic acid derivatives which have an inhibitory activity on glycerophosphate dehydrogenase and lactate dehydrogenase.</p>
    <p>Euoropean Patent Specification EP 0 675 110 A1 describes 1H-indole-3-glyoxylamides which are profiled as sPLA2 inhibitors and are used in the treatment of septic shock, in pancreatitis, and in the treatment of allergic rhinitis and rheumatoid arthritis.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>The aim of the present invention is to make available novel compounds from the indolyl-3-glyoxylic acid series, which have antiasthmatic and immunomodulating action.</p>
    <p>The chemical processes for the preparation of these compounds and pharmaceutical processes for the conversion of the novel compounds into medicaments and their preparation forms are furthermore described.</p>
    <p>The subject matter of the invention comprises compounds of the general formula I, ##STR1## where the radicals R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and Z have the following meaning:</p>
    <p>R=hydrogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, where the alkyl group can be mono- or polysubstituted by the phenyl ring. This phenyl ring, for its part, can be mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, by carboxyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, benzyloxy groups and by a benzyl group which is mono- or polysubstituted in the phenyl moiety by (C<sub>1</sub> -C<sub>6</sub>)-alkyl groups halogen atoms or trifluoromethyl groups.</p>
    <p>R<sub>1</sub> can be a phenyl ring which is mono- or polysubstituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, hydroxyl, benzyloxy, nitro, amino, (C<sub>1</sub> -C<sub>6</sub>)-alkylamino, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy-carbonylamino and by a carboxyl group or a carboxyl group esterified by (C<sub>1</sub> -C<sub>6</sub>)-alkanols, or is a pyridin structure of the formula II ##STR2## where the pyridin structure is alternatively bonded to the ring carbon atoms 2, 3 and 4 and can be substituted by the substitutents R<sub>5</sub> and R<sub>6</sub>. The radicals R<sub>5</sub> and R<sub>6</sub> can be identical or different and have the meaning (C<sub>1</sub> -C<sub>6</sub>)-alkyl, and also the meaning (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, nitro, amino, hydroxyl, halogen and trifluoromethyl and are furthermore the ethoxycarbonylamino radical and the group carboxyalkyloxy in which the alkyl group can have 1-4 C atoms.</p>
    <p>R<sub>1</sub> can furthermore be a 2- or 4-pyrimidinyl-heterocycle or a pyridylmethyl radical in which CH<sub>2</sub> can be in the 2-, 3-, 4-position where the 2-pyrimidinyl ring can be mono- or polysubstituted by the methyl group, furthermore are [sic] the 2-, 3- and 4-quinolyl structure substituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, halogen, the nitro group, the amino group and the (C<sub>1</sub> -C<sub>6</sub>)-alkylamino radical, or are [sic] a 2-, 3- and 4-quinolylmethyl group, where the ring carbons of the pyridylmethyl and quinolylmethyl radical can be substituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, nitro, amino and (C<sub>1</sub> -C<sub>6</sub>)-alkoxy-carbonylamino.</p>
    <p>R<sub>1</sub> for the case where R is hydrogen or the benzyl group, can furthermore be the acid radical of a natural or unnatural amino acid, e.g. the α-glycyl, the α-sarcosyl, the α-alanyl, the α-leucyl, the α-isoleucyl, the α-seryl, the α-phenylalanyl, the α-histidyl, the α-prolyl, the α-arginyl, the α-lysyl, the α-asparagyl and the α-glutamyl radical, where the amino groups of the respective amino acids can be present in unprotected or protected form. Possible protective groups for the amino function are the carbobenzoxy radical (Z radical) and the tert-butoxycarbonyl radical (BOC radical) and also the acetyl group. In the case of the asparagyl and glutamyl radical claimed for R<sub>1</sub>, the second, nonbonded carboxyl group is present as a free carboxyl group or in the form of an ester with C<sub>1</sub> -C<sub>6</sub> -alkanols, e.g. as the methyl, ethyl or as the tert-butyl ester. R<sub>1</sub> can furthermore be the allylaminocarbonyl-2-methylprop-1-yl group. R and R<sub>1</sub>, together with the nitrogen atom to which they are bonded, can furthermore form a piperazine ring of the formula III or a homopiperazine ring if R<sub>1</sub> is an aminoalkylene group in which ##STR3## R<sub>7</sub> is an alkyl radical, a phenyl ring which can be mono- or polysubstituted by (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, halogen, the nitro group, the amino function, by (C<sub>1</sub> -C<sub>6</sub>)-alkylamino, the benzhydryl group and the bis-p-fluorobenzylhydryl group.</p>
    <p>R<sub>2</sub> can be hydrogen or the (C<sub>1</sub> -C<sub>6</sub>)-alkyl group, where the alkyl group can be mono- or polysubstituted by halogen and phenyl which for its part can be mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carboxyl groups, carboxyl groups esterified with (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups or benzyloxy groups. The (C<sub>1</sub> -C<sub>6</sub>)-alkyl group counting as R<sub>2</sub> can furthermore be substituted by the 2-quinolyl group and the 2-, 3- and 4-pyridyl structure, which in each case can both be mono- or polysubstituted by halogen, (C<sub>1</sub> -C<sub>4</sub>)-alkyl groups or (C<sub>1</sub> -C<sub>4</sub>)-alkoxy groups. R<sub>2</sub> is furthermore the aroyl radical, where the aroyl moiety on which this radical is based is the phenyl ring which can be mono- or polysubstituted by halogen (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, carboxyl groups, carboxyl groups esterified by (C<sub>1</sub> -C<sub>6</sub>)-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups or benzyloxy groups.</p>
    <p>R<sub>3</sub> and R<sub>4</sub> can be identical or different and are hydrogen, hydroxyl, (C<sub>1</sub> -C<sub>6</sub>)-alkyl, (C<sub>3</sub> -C<sub>7</sub>)-cycloalkyl, (C<sub>1</sub> -C<sub>6</sub>)-alkanoyl, (C<sub>1</sub> -C<sub>6</sub>)-alkoxy, halogen and benzyloxy. R<sub>3</sub> and R<sub>4</sub> can furthermore be the nitro group, the amino group, the (C<sub>1</sub> -C<sub>4</sub>)-mono- or dialkyl-substituted amino group, and the (C<sub>1</sub> -C<sub>3</sub>)-alkoxycarbonylamino function or (C<sub>1</sub> -C<sub>3</sub>)-alkcoxycarbonylamino-(C<sub>1</sub> -C<sub>3</sub>)-alkyl function.</p>
    <p>Z is O or S</p>
    <p>The designation alkyl, alkanol, alkoxy or alkylamino group for the radicals R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> is normally to be understood as meaning "straight-chain" and "branched" alkyl groups, where "straight-chain alkyl groups" can be, for example, radicals such as methyl, ethyl, n-propyl, n-butyl, n-pentyl and n-hexyl and "branched alkyl groups" designate, for example, radicals such as isopropyl or tert-butyl. "Cycloalkyl" is to be understood as meaning radicals such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. The designation "halogen" represents fluorine, chlorine, bromine or iodine. The designation "alkoxy group" represents radicals such as, for example, methoxy, ethoxy, propoxy, butoxy, isopropoxy, isobutoxy or pentoxy.</p>
    <p>The compounds according to the invention can also be present as acid addition salts, for example as salts of mineral acids, such as, for example, hydrochloric acid, sulfuric acid, phosphoric acid, salts of organic acids, such as, for example, acetic acid, lactic acid, malonic acid, maleic acid, fumaric acid, gluconic acid, glucuronic acid, citric acid, embonic acid, methanesulfonic acid, trifluoroacetic acid and succinic acid.</p>
    <p>Both the compounds of the formula I and their salts are biologically active. The compounds of the formula 1 can be administered in free form or as salts with a physiologically tolerable acid. Administration can be carried out orally, parenterally, intravenously, transdermally or by inhalation.</p>
    <p>The invention furthermore relates to pharmaceutical preparations containing at least one compound of the formula I or its salt with physiologically tolerable inorganic or organic acids and, if appropriate, pharmaceutically utilizable excipients and/or diluents or auxiliaries.</p>
    <p>Suitable administration forms are, for example, tablets, coated tablets, capsules, solutions or ampoules, suppositories, patches, powder preparations which can be inhaled, suspensions, creams and ointments.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p>The compounds according to the invention have a good antiasthmatic, antiallergic and immunosuppressant/immunomodulating action, for example in transplantations and diseases such as psoriasis, rheumatoid disorders and chronic polyarthritis, in the following pharmacological models:</p>
    <p>Inhibition of the "Late Phase" Eosinophilia in the BAL 24 Hours After Allergen Challenge in Guinea Pigs</p>
    <p>Male guinea pigs (200-250 g, Dunkin Hartley Shoe) were actively sensitized subcutaneously with ovalbumin (10 μg of ovalbumin+1 mg of Al(OH)<sub>3</sub>) and boosted 2 weeks later. One week after boosting with ovalbumin, the animals were exposed to an inhalation challenge with ovalbumin (0.5% strength solution) for 20-30 seconds. 24 hours later, the animals were killed by means of an overdose of urethane, exsanguinated and a bronchoalveolar lavage (BAL) was carried out using 2×5 ml of 0.9% strength physiological saline solution.</p>
    <p>The lavage fluid was collected and centrifuged at 400 g for 10 minutes, and the pellets were suspended in 1 ml of 0.9% strength physiological saline solution. The eosinophils were counted microscopically in a Neubauer chamber after staining by means of Becton Dickinson test kit No. 5877. This test kit contains Phloxin B as a selective stain for eosinophils. The eosinophils in the BAL was [sic] counted here for each animal and expressed as eosinophils (millions/animal). For each group the mean value and standard deviation were determined. The percentage inhibition of eosinophilia for the group treated with test substance was calculated according to the following formula:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">(A-B)-(B-C)/(A-C)×100=% inhibition</pre>
    
    <p>in this formula A eosinophils correspond to the untreated challenge group, B eosinophils to the treated group and C eosinophils to the unchallenged control group.</p>
    <p>The animals were treated with a histamine H<sub>1</sub> antagonist (azelastine; 0.01 mg/kg p.o.) 2 hours before allergen challenge to avoid death. The administration of the test substances or of the vehicle was carried out 4 hours after allergen challenge. The percentage inhibition of eosinophilia in the BAL was calculated on groups of 6-10 animals.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE______________________________________eosinophiliaf the "late phase"24 h after allergen challenge in guinea pigs      DoseSubstance  [mg/kg]  Administration                           n    % Inhibition______________________________________Cyclosporin A       5       i.p. + 4 h  17   50.0      10       i.p. + 4 h  11   47.0      30       p.o. + 4 h  10   68.8According to Ex. 1       5       i.p. + 4 h  10   27.8      10       i.p. + 4 h  10   55.4      30       p.o. + 4 h   9   56.1______________________________________</pre>
    
    <p>Assays for the Determination of Peptidylprolyl Isomerase (PPIase) Activity and Inhibition</p>
    <p>The PPIase activity of the cyclophilins was measured enzymatically according to Fischer et al. (1984). After isomerization of the substrate by the peptidyl prolyl isomerase, this is accessible to chymotrypsin, which cleaves the chromophore p-nitroaniline. For the determination of inhibition of the PPIase activity by substance, recombinant human Cyp B was used. The interaction of Cyp B with a potential inhibitor was carried out as follows:</p>
    <p>A certain concentration of purified Cyp B was incubated with 1 μM substance for 15 min. The PPIase reaction was started by addition of the substrate solution to the reaction mixture which contains HEPES buffer, chymotrypsin and either test or control samples. Under these conditions, first-order kinetics were obtained with a constant K<sub>observed</sub> =K<sub>0</sub> +K<sub>enz</sub>, where K<sub>0</sub> is the spontaneous isomerization and K<sub>enz</sub> is the rate of isomerization of the PPIase activity. The extinction values which correspond to the amount of the chromophore cleaved were measured using a Beckman DU 70 spectrophotometer at a constant reaction temperature of 10° C. The observed residual activity in the presence of various substances was compared with the cyclophilins only treated with solvent. The results were given in % residual activity. Cyclosporin A (CsA) was used as the reference compound. The inhibition of the PPIase activity was additionally checked by SDS-PAGE.</p>
    <p>Colorimetric Assay (Based on the MTT Test) for the Non-Radioactive Quantification of Cell Proliferation and Survival Ability</p>
    <p>MTT is used for the quantitative determination of cell proliferation and activation, for example, in the reaction on growth factors and cytokines such as IL-2 and IL-4 and also for the quantification of the antiproliferative or toxic effects.</p>
    <p>The assay is based on the cleavage of yellow tetrazolium salt MTT to give purple-red formazan crystals by metabolically active cells.</p>
    <p>The cells, cultured in a 96-hole tissue culture plate, are incubated for about 4 h with yellow MTT solution. After this incubation time, purple-red formazan salt crystals are formed. These salt crystals are insoluble in aqueous solutions, but can be dissolved by addition of solubilizer and by incubation of the plates overnight.</p>
    <p>The dissolved formazan product is quantified spectrophotometrically using an ELISA reader. An increase in the number of living cells results in an increase in the total metabolic activity in the sample. This increase correlates directly with the amount of the purple-red formazan crystals formed, which are [sic] measured by the absorption.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________                 Inhibition of                 CD3-induced Inhibition of                 IL-2        lympho-      Inhibition of                 production  proliferationSubstance  PPIase activity                 [%]         [%]Conc. [μM]      [%]        0.1    1   10   0.1 1    10______________________________________According to Ex. 1      80-100     34     72  95   18  39   61Cyclosporin A      80-100     56     82  94    8   7   11______________________________________</pre>
    
    <p>The processes for the preparation of the compounds according to the invention are described in the following reaction schemes 1 and 2 and in general procedures. All compounds can be prepared as described or analogously.</p>
    <p>The compounds of the general formula I are obtainable according to the following Scheme 1, shown for the synthesis of the compound Example 1: ##STR4## General Procedure for the Preparation of the Compounds of the General Formula I According to Scheme 1</p>
    <p>1st Stage</p>
    <p>The indole derivative, which can be unsubstituted or mono- or polysubstituted on C-2 or in the phenyl structure, is dissolved in a protic, dipolar aprotic or nonpolar organic solvent, such as, for example, isopropanol, tetrahydrofuran, dimethyl sulfoxide, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, dioxane, toluene or methylene chloride and added dropwise to a suspension of a base in a molar or excess amount prepared in a 3-necked flask under an N<sub>2</sub> atmosphere, such as, for example, sodium hydride, powdered potassium hydroxide, potassium tert-butoxide, dimethylaminopyridine or sodium amide in a suitable solvent. The desired alkyl, aralkyl or heteroaralkyl halide, if appropriate with addition of a catalyst, such as, for example, copper, is then added and the mixture is reacted for some time, for example 30 minutes to 1.2 hours, and the temperature is kept within a range from 0° C. to 120° C., preferably between 30° C. to [sic] 80° C., particularly between 50° C. and 65° C. After completion of the reaction, the reaction mixture is added to water, the solution is extracted, for example, with diethyl ether, dichloromethane, chloroform, methyl tert-butyl ether or tetrahydrofuran and the organic phase obtained in each case is dried using anhydrous sodium sulfate. The organic phase is concentrated in vacuo, the residue which remains is crystallized by trituration or the oily residue is purified by recrystallization, distillation or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of dichloromethane and diethyl ether in the ratio 8:2 (vol/vol) or a mixture of dichloromethane and ethanol in the ratio 9:1 (vol/vol).</p>
    <p>2nd Stage</p>
    <p>The N-substituted indole obtained by the abovementioned 1st stage procedure is dissolved under a nitrogen atmosphere in an aprotic or nonpolar organic solvent, such as, for example, diethyl ether, methyl tert-butyl ether, tetrahydrofuran, dioxane, toluene, xylene, methylene chloride or chloroform and added to a solution, prepared under a nitrogen atmosphere, of a simply molar up to 60 percent excess amount of oxalyl chloride in an aprotic or nonpolar solvent, such as, for example, in diethyl ether, methyl tert-butylether, tetrahydrofuran, dioxane, toluene, xylene, methylene chloride or chloroform, the temperature being kept between -5° C. and 20° C. The reaction solution is then heated at a temperature between 10° C. and 130° C., preferably between 20° C. and 80° C., particularly between 30° C. and 50° C., for a period of 30 minutes up to 5 hours and the solvent is then evaporated. The residue of the "indolyl-3-glyoxylic acid chloride" formed in this manner which remains is dissolved in an aprotic solvent such as, for example, tetrahydrofuran, dioxane, diethyl ether, toluene or alternatively in a dipolar aprotic solvent, such as, for example, dimethylformamide, dimethylacetamide or dimethyl sulfoxide, cooled to a temperature between 10° C. and -15° C., preferably between -5° C. and 0° C., and treated in the presence of an acid scavenger with a solution of the primary or secondary amine in a diluent.</p>
    <p>Possible diluents are the solvents used above for the dissolution of the indolyl-3-glyoxylic acid chloride. Acid scavengers used are triethylamine, pyridin, dimethylaminopyridine, basic ion exchanger, sodium carbonate, potassium carbonate, powdered potassium hydroxide and excess primary or secondary amine employed for the reaction. The reaction takes place at a temperature from 0° C. to 120° C., preferably at 20-80° C., particularly between 40° C. and 60° C. After a reaction time of 1-3 hours and standing at room temperature for 24 hours, the hydrochloride of the acid scavenger is filtered, the filtrate is concentrated in vacuo, and the residue is recrystallized from an organic solvent or purified by column chromatography on silica gel or alumina. The eluent used is, for example, a mixture of dichloromethane and ethanol (95:5, vol/vol).</p>
    <heading>WORKING EXAMPLES</heading> <p>According to this general procedure for Stages 1 and 2, on which the synthesis Scheme 1 is based, the following compounds were synthesized which are evident from the following survey detailing the respective chemical name. In Table 1 which follows, the structures of these compounds and their melting points can be seen from the general formula I and the substituents R<sub>1</sub> -R<sub>4</sub> and Z:</p>
    <heading>Example 1</heading> <heading>N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <p>1st Stage</p>
    <heading>1-(4-Fluorobenzyl)indole</heading> <p>A solution of 11.72 g (0.1 mol) of indole in 50 ml of dimethyl sulfoxide is added to a mixture of 2.64 g of sodium hydride (0.11 mol, mineral oil suspension) in 100 ml of dimethyl sulfoxide. The mixture is heated for 1.5 hours at 60° C., then allowed to cool and 15.9 g (0.11 mol) of 4-fluorobenzyl chloride are added dropwise. The solution is warmed to 60° C., allowed to stand overnight and then poured into 400 ml of water with stirring. The mixture is extracted several times with a total of 150 ml of methylene chloride, the organic phase is dried using anhydrous sodium sulfate and filtered, and the filtrate is concentrated in vacuo. The residue is distilled in a high vacuum: 21.0 g (96% of theory) B.p. (0.5 mm): 140° C.</p>
    <p>2nd Stage</p>
    <heading>N-(pyridin-4-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <p>A solution of 4.75 g (21.1 mmol) of 1-(4-fluorobenzyl)indole in 25 ml of ether is added dropwise at 0° C. and under N<sub>2</sub> to a solution of 2.25 ml of oxalyl chloride in 25 ml of ether. The mixture is refluxed for 2 hours and the solvent is then evaporated. 50 ml of tetrahydrofuran were [sic] then added to the residue, and the solution is cooled to -5° C. and treated dropwise with a solution of 4.66 g (49.5 mmol) of 4-aminopyridine in 200 ml of THF. The mixture is refluxed for 3 hours and allowed to stand at room temperature overnight. The 4-aminopyridine hydrochloride is filtered off with suction, the precipitate is washed with THF, the filtrate is concentrated in vacuo and the residue is recrystallized from ethyl acetate.</p>
    <p>Yield: 7.09 g (90% of theory)</p>
    <p>Melting point: 225-226° C.</p>
    <p>Elemental analysis: Calc. C 70.77 H 4.32 N 11.25 Found C 71.09 H 4.36 N 11.26</p>
    <heading>Example 2</heading> <heading>N-(Pyridin-4-yl)-(1-methylindol-3-yl)glyoxylamide</heading> <heading>Example 3</heading> <heading>N-(Pyridin-3-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <heading>Example 4</heading> <heading>N-(Pyridin-3-yl)-(1-benzylindol-3-yl)glyoxylamide</heading> <heading>Example 5</heading> <heading>N-(Pyridin-3-yl)-[1-(2-chlorobenzyl)indol-3-yl]glyoxylamide</heading> <heading>Example 6</heading> <heading>N-(4-Fluorophenyl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <heading>Example 7</heading> <heading>N-(4-Nitrophenyl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <heading>Example 8</heading> <heading>N-(2-Chloropyridin-3-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <heading>Example 9</heading> <heading>N-(Pyridin-4-yl)-(1-benzylindol-3-yl)glyoxylamide</heading> <heading>Example 10</heading> <heading>N-(Pyridin-4-yl)-[1-(3-pyridylmethyl)indol-3-yl]glyoxylamide</heading> <heading>Example 11</heading> <heading>N-(4-Fluorophenyl)-[1-(2-pyridylmethyl)indol-3-yl]glyoxylamide</heading> <heading>Example 12</heading> <heading>N-4(Fluorophenyl)-[1-(3-pyridylmethyl)indol-3-yl]glyoxylamide</heading> <heading>Example 13</heading> <heading>N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)indol-3-yl]glyoxylamide</heading> <heading>Example 14</heading> <heading>N-(Pyridin-4-yl)-[1-(2-chlorobenzyl)indol-3-yl]glyoxylamide</heading> <heading>Example 15</heading> <heading>N-(Pyridin-2-yl)-[1-4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <heading>Example 16</heading> <heading>N-(Pyridin-4-yl)-[1-(2-pyridylmethyl)indol-3-yl]glyoxylamide</heading> <heading>Example 17</heading> <heading>(4-Phenylpiperazin-1-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <heading>Example 18</heading> <heading>N-(Pyridin-2-yl)-(1-benzylindol-3-yl)glyoxylamide</heading> <heading>Example 19</heading> <heading>N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)-6-ethoxycarbonylaminoindol-3-yl]glyoxylamide</heading> <heading>Example 20</heading> <heading>N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)-5-ethoxycarbonylaminoindol-3-yl]glyoxylamide</heading> <heading>Example 21</heading> <heading>N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)-6-cyclopentyloxycarbonylaminoindol-3-yl]glyoxylamide</heading> <heading>Example 22</heading> <heading>4-(Pyridin-4-yl)-piperazin-1-yl)-[1-(4-fluorobenzyl)indol-3-yl]-glyoxylamid</heading> <heading>Example 23</heading> <heading>N-(3,4,5-Trimethoxybenzyl)-N-(allylaminocarbonyl-2-methylprop-1-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <heading>Example 24</heading> <heading>N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)-5-methoxyindol-3-yl]glyoxylamide</heading> <heading>Example 25</heading> <heading>N-(Pyridin-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide</heading> <heading>Example 26</heading> <heading>N-pyridin-4-yl-[1-(4-fluorobenzyl)-5-ethoxycarbonylaminomethylindol-3-yl]glyoxylamide</heading> <p>
      </p> <pre xml:space="preserve" listing-type="tabular">TABLE 1   - Novel indolylglyoxylamides according to reaction Scheme 1   Formula 1  ##STR5## Example R R<sub>1</sub> R<sub>2</sub> R<sub>3</sub> R<sub>4</sub> Z M.p.   Ex. 1 H  ##STR6##  ##STR7##  H H O 225-6°  C.                Ex. 2 H  ##STR8##  CH<sub>3</sub> H H O 176°  C.                       Ex. 3 H  ##STR9##  ##STR10##  H H O 173°  C.              Ex. 4 H  ##STR11##  ##STR12##  H H O 140°  C.              Ex. 5 H  ##STR13##  ##STR14##  H H O 185°  C.              Ex. 6 H  ##STR15##  ##STR16##  H H O 199°  C.              Ex. 7 H  ##STR17##  ##STR18##  H H O &gt;250°  C.               Ex. 8 H  ##STR19##  ##STR20##  H H O 149°  C.              Ex. 9 H  ##STR21##  ##STR22##  H H O 178-180°  C.                  Ex. 10 H  ##STR23##  ##STR24##  H H O 179°  C.              Ex. 11 H  ##STR25##  ##STR26##  H H O 132°  C.              Ex. 12 H  ##STR27##  ##STR28##  H H O 144°  C.              Ex. 13 H  ##STR29##  ##STR30##  H H O 234°  C.              Ex. 14 H  ##STR31##  ##STR32##  H H O 184°  C.              Ex. 15 H  ##STR33##  ##STR34##  H H O 141°  C.              Ex. 16 H  ##STR35##  ##STR36##  H H O 202°  C.   Ex. 17  ##STR37##  ##STR38##  H H O 115°  C.   Ex. 18 H  ##STR39##  ##STR40##  H H O 112-3°  C.                Ex. 19 H  ##STR41##  ##STR42##  6-NHCOOEt H O &gt;250°  C.                       Ex. 20 H  ##STR43##  ##STR44##  5-NHCOOEt H O 183°  C.                      Ex. 21 H  ##STR45##  ##STR46##  ##STR47##  H O oily   Ex. 22  ##STR48##  ##STR49##  H H O 160-62°  C.   Ex. 23  ##STR50##  ##STR51##  ##STR52##  H H O 139-141°  C.                  Ex. 24 H  ##STR53##  ##STR54##  5-OCH<sub>3</sub> H O 188°  C.                        Ex. 25 H  ##STR55##  ##STR56##  5-OH H O &gt;250°  C.                  Ex. 26 H  ##STR57##  ##STR58##  6-CH<sub>2</sub> --NHCOOEt H O 175-176°  C.</pre>
    
    <p>Starting Materials for the Compounds of the General Formula 1 Prepared According to Synthesis Scheme 1, which come from Table 1</p>
    <p>All precursors for the final synthesis stages of Examples 1 to 22 and 24 to 26 are commercially available.</p>
    <p>Furthermore, the compounds of the general formula I are also obtainable according to the synthesis route of Scheme 2, shown by the synthesis of the compound Example 27: ##STR59## General Procedure for the Preparation of the Compounds of the General Formula 1 According to Scheme 2</p>
    <p>1st Stage</p>
    <p>The indole derivative dissolved in a solvent, such as given above for oxalyl chloride, which can be unsubstituted or substituted on C-2 or in the phenyl ring, is added dropwise at a temperature between -5° C. and +5° C. to a solution of a simply molar up to 60% excess amount of oxalyl chloride prepared under a nitrogen atmosphere in an aprotic or nonpolar solvent, such as, for example, in diethyl ether, methyl tert-butyl ether, tetrahydrofuran, dioxane or alternatively dichloromethane. The reaction solution is then heated for 1 to 5 hours to a temperature between 10° C. and 120° C., preferably between 20° C. and 80° C., particularly between 30° C. and 60° C., and the solvent is then evaporated. The residue of the (indol-3-yl)glyoxylic acid chloride which remains is dissolved or suspended in an aprotic solvent, such as, for example, tetrahydrofuran, dioxane, diethyl ether, toluene or alternatively in a dipolar aprotic solvent, such as, for example, dimethylformamide, dimethylacetamide or dimethyl sulfoxide, cooled to a temperature between -10° C. and +10° C., preferably to -5° C. to 0° C., and treated with a solution of the primary or secondary amine in a diluent in the presence of an acid scavenger. Possible diluents are the solvents used for the dissolution of the "indolyl-3-glyoxylic acid chloride". Acid scavengers used are triethylamine, pyridin, dimethylaminopyridine, basic ion exchanger, sodium carbonate, potassium carbonate, powdered potassium hydroxide and excess primary or secondary amine employed for the reaction. The reaction takes place at a temperature from 0° C. to 120° C., preferably at 20-80° C., particularly between 40° C. and 60° C. After a reaction time of 1-4 hours and standing at room temperature for 24 hours, the precipitate is digested with water, and the solid is filtered off with suction and dried in vacuo. The desired compound is purified by recrystallization in an organic solvent or by column chromatography on silica gel or alumina. The solvent used is, for example, a mixture of dichloromethane and ethanol (10:1, vol/vol).</p>
    <p>2nd Stage</p>
    <p>The "indol-3-ylglyoxylamide" obtained according to the abovementioned 1st Stage procedure is dissolved in a protic, dipolar aprotic or nonpolar organic solvent, such as, for example, in isopropanol, tetrahydrofuran, dimethyl sulfoxide, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, dioxane, toluene or methylene chloride and added dropwise to a suspension of a base such as, for example, sodium hydride, powdered potassium hydroxide, potassium tert-butoxide, dimethylaminopyridine or sodium amide in a suitable solvent, in a molar amount or in excess prepared in a 3-necked flask under an N<sub>2</sub> atmosphere. The desired alkyl, aralkyl or heteroaralkyl halide is then added either in undiluted form or in a diluent which was also used, for example, to dissolve the "indol-3-yl glyoxylamide", if appropriate with addition of a catalyst, such as, for example, copper, and the mixture is allowed to react for some time, e.g. 30 minutes to 12 hours, and the temperature is kept within a range between 0° C. and 120° C., preferably between 30° C. and 80° C., particularly between 50 and 70° C. After completion of the reaction, the reaction mixture is added to water, the solution is extracted, for example, with diethyl ether, dichloromethane, chloroform, methyl tert-butyl ether, tetrahydrofuran or N-butanol and the organic phase obtained in each case is dried using anhydrous sodium sulfate. The organic phase is concentrated in vacuo, the residue which remains is crystallized by trituration or the oily residue is purified by distillation or by column chromatography or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methylene chloride and diethyl ether in the ratio 8:2 (vol/vol) or a mixture of methylene chloride and ethanol in the ratio 9:1 (v/v).</p>
    <heading>WORKING EXAMPLES</heading> <p>According to this general procedure for Stages 1 and 2, on which synthesis Scheme 2 is based, compounds were synthesized which have already been prepared according to the synthesis course of reaction Scheme 1 and are evident from Table 1. The relevant precursors of these compounds are evident from Table 2.</p>
    <heading>Example 27</heading> <heading>N-(pyridin-4-yl)-[1-(4-flurobenzyl)indol-3-yl]glyoxylamide</heading> <p>(Final substance, identical to Example 1)</p>
    <p>1st Stage</p>
    <heading>N-(Pyridin-4-yl)-(indol-3-yl)glyoxylamide</heading> <p>A solution of 10 g (85.3 mmol) of indole in 100 ml of ether is added dropwise at 0° C. to a solution of 9 ml of oxalyl chloride in 100 ml of anhydrous ether. The mixture is kept under reflux for 3 hours. A suspension of 12 g (127.9 mmol) of 4-aminopyridine in 500 ml of tetrahydrofuran is then added dropwise at -5° C., and the reaction mixture is heated to reflux temperature with stirring for 3 hours and allowed to stand overnight at room temperature. The precipitate is filtered and treated with water and the dried compound is purified on a silica gel column (silica gel 60, Merck AG, Darmstadt) using the eluent methylene chloride/ethanol (10:1, v/v).</p>
    <p>Yield: 9.8 g (43.3% of theory)</p>
    <p>M.p.: from 250° C.</p>
    <p>2nd Stage</p>
    <heading>N-(Pyridin-4-yl)-[1-[4-fluorobenzylindol-3-yl]glyoxylamide</heading> <p>The N-(pyridin-4-yl)-(indol-3-yl)glyoxylamide obtained according to the 1st stage is reacted with 4-fluorobenzyl chloride according to the "benzylation procedure" (Page 11) and the compound obtained is isolated.</p>
    <p>Yield: 41% of theory</p>
    <p>M.p.: 224-225° C.</p>
    <p>Elemental analysis: Calc. C 70.77 H 4.32 N 11.25 Found C 70.98 H 4.40 N 11.49</p>
    <heading>Example 28</heading> <heading>N-(4-Nitrophenyl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <p>(Final substance, identical to Example 7)</p>
    <heading>Example 29</heading> <heading>N-(4-Fluorophenyl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <p>(Final substance, identical to Example 6)</p>
    <heading>Example 30</heading> <heading>N-)Pyridin-3-yl)-[1-(4-fluorobenzyl)indol-3-yl]glyoxylamide</heading> <p>(Final substance, identical to Example 3)</p>
    <p>The following precursors (1st stage of reaction scheme 2, Table 2) were obtained according to the present Scheme 2.</p>
    <heading>Example 31</heading> <heading>N-(Pyridin-4-yl)-(indol-3-yl)glyoxylamide</heading> <heading>Example 32</heading> <heading>N-(4-Nitrophenyl)-(indol-3-yl)glyoxylamide</heading> <heading>Example 33</heading> <heading>N-(4-Fluorophenyl)-(indol-3-yl)glyoxylamide</heading> <heading>Example 34</heading> <heading>N-(Pyridin-3-yl)-(indol-3-yl)glyoxylamide</heading> <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 2__________________________________________________________________________Novel indolylglyoxylamides according to reaction Scheme 2  #STR60## Formula 1ExampleR R<sub>1</sub>     R<sub>2</sub>                 R<sub>3</sub>                    R<sub>4</sub>                       Z  M.p.__________________________________________________________________________  Ex. 31 H                            H H H O &gt;250° C.   - Ex. 32 H                            H H H O &gt;250° C.   - Ex. 33 H                            H H H O 233-5° C.   - Ex. 34 H                            H H H O 235° C.__________________________________________________________________________</pre>
    
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3135794">US3135794</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 18, 1960</td><td class="patent-data-table-td patent-date-value">Jun 2, 1964</td><td class="patent-data-table-td ">Sterling Drug Inc</td><td class="patent-data-table-td ">1-(n, n-dibenzylamino)-2-[n&#39;-(halo-loweralkanoyl)-n&#39;-(substituted)]-loweralkylenediamines</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3801594">US3801594</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 28, 1972</td><td class="patent-data-table-td patent-date-value">Apr 2, 1974</td><td class="patent-data-table-td ">American Cyanamid Co</td><td class="patent-data-table-td ">Substituted heteroethyleneindoles and acid addition salts thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0675110A1?cl=en">EP0675110A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 31, 1995</td><td class="patent-data-table-td patent-date-value">Oct 4, 1995</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">1H-Indole-3-glyoxylamide sPLA2 inhibitors</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Archibald et al., "<a href='http://scholar.google.com/scholar?q="1%2C4-Bis%282-indol-3-ylethyl%29piperazines%2C"'>1,4-Bis(2-indol-3-ylethyl)piperazines,</a>" J. Med. Chem., vol. 17, No. 7, pp. 745-747, 1974.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Archibald et al., 1,4 Bis(2 indol 3 ylethyl)piperazines, J. Med. Chem., vol. 17, No. 7, pp. 745 747, 1974.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chem. Abstr. 115007v American Home Products, "<a href='http://scholar.google.com/scholar?q="Therapeutic+bis%28indolyl%29+compounds%2C"'>Therapeutic bis(indolyl) compounds,</a>" vol. 70, p. 15007, 1969.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chem. Abstr. 115007v American Home Products, Therapeutic bis(indolyl) compounds, vol. 70, p. 15007, 1969.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chem. Abstr. 120:125105r Evans et al., "<a href='http://scholar.google.com/scholar?q="Probing+the+5-HT3+receptor+site+using+novel+indole-3-glyoxylic+acid+derivatves%2C"'>Probing the 5-HT3 receptor site using novel indole-3-glyoxylic acid derivatves,</a>" vol. 120, p. 123, 1994.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chem. Abstr. 120:125105r Evans et al., Probing the 5 HT3 receptor site using novel indole 3 glyoxylic acid derivatves, vol. 120, p. 123, 1994.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chem. Abstr. 37598x Podwinski, "<a href='http://scholar.google.com/scholar?q="Synthesis+of+some+5-benzyloxyindole-3-glyoxylic+acid+amides%2C"'>Synthesis of some 5-benzyloxyindole-3-glyoxylic acid amides,</a>" vol. 70, p. 327, 1969.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chem. Abstr. 37598x Podwinski, Synthesis of some 5 benzyloxyindole 3 glyoxylic acid amides, vol. 70, p. 327, 1969.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chem. Abstr. 3871 P eng et al., Synthesis of derivatives of 5,6 disubstituted 3 (Beta aminoethyl) indole, vol. 65, 1966.</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chem. Abstr. 3871 P'eng et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+of+derivatives+of+5%2C6-disubstituted+3-%28Beta-aminoethyl%29-indole%2C"'>Synthesis of derivatives of 5,6-disubstituted 3-(Beta-aminoethyl)-indole,</a>" vol. 65, 1966.</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chem. Abstr. 53968m Bertaccini et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+and+Pharmacological+activity+of+some+5-methoxyindole+derivatives+occurring+in+nature%2C"'>Synthesis and Pharmacological activity of some 5-methoxyindole derivatives occurring in nature,</a>" vol. 67, p. 5069, 1967.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chem. Abstr. 53968m Bertaccini et al., Synthesis and Pharmacological activity of some 5 methoxyindole derivatives occurring in nature, vol. 67, p. 5069, 1967.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chem. Abstr. 86: 106379w Alvarez et al., "<a href='http://scholar.google.com/scholar?q="3-%282-Aminoethyl%29indole+derivatives%2C"'>3-(2-Aminoethyl)indole derivatives,</a>" vol. 86, p. 491, 1977.</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chem. Abstr. 86: 106379w Alvarez et al., 3 (2 Aminoethyl)indole derivatives, vol. 86, p. 491, 1977.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chem. Abstr. 87491p Brewster et al., "<a href='http://scholar.google.com/scholar?q="Antihypertensive+1%2C4-bis%282-indol-3-ylethyl%29piperazines%2C"'>Antihypertensive 1,4-bis(2-indol-3-ylethyl)piperazines,</a>" vol. 79, p. 27, 1973.</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chem. Abstr. 87491p Brewster et al., Antihypertensive 1,4 bis(2 indol 3 ylethyl)piperazines, vol. 79, p. 27, 1973.</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chem. Abstr. 92: 128647h. CXIV. Eryshev et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+of+anilides+of+indolylalkanoic+acids%2C"'>Synthesis of anilides of indolylalkanoic acids,</a>" vol. 92, p. 673, 1980.</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chem. Abstr. 92: 128647h. CXIV. Eryshev et al., Synthesis of anilides of indolylalkanoic acids, vol. 92, p. 673, 1980.</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chem. Abstr. 9293 Sterling Drug Inc., "<a href='http://scholar.google.com/scholar?q="Indolylpiperazines%2C"'>Indolylpiperazines,</a>" vol. 60, 1964.</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chem. Abstr. 9293 Sterling Drug Inc., Indolylpiperazines, vol. 60, 1964.</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Domschke et al., "<a href='http://scholar.google.com/scholar?q="Notiz+zur+Darstellung+einiger+%5B1-Benzyl-2-methyl-5-methoxy-indolyl-%283%29%5D-glyoxylsaureamide%2C"'>Notiz zur Darstellung einiger [1-Benzyl-2-methyl-5-methoxy-indolyl-(3)]-glyoxylsaureamide,</a>" vol. 94, pp. 2353-2355, 1961.</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Domschke et al., Notiz zur Darstellung einiger 1 Benzyl 2 methyl 5 methoxy indolyl (3) glyoxylsaureamide, vol. 94, pp. 2353 2355, 1961.</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Evans et al., "<a href='http://scholar.google.com/scholar?q="Probing+the+5-HT3+receptor+site+using+novel+indole-3-glyoxylic+acid+derivatives%2C"'>Probing the 5-HT3 receptor site using novel indole-3-glyoxylic acid derivatives,</a>" Med. Chem. Res., 3(5-6), pp. 386-406, 1993.</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Evans et al., Probing the 5 HT3 receptor site using novel indole 3 glyoxylic acid derivatives, Med. Chem. Res., 3(5 6), pp. 386 406, 1993.</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Glamkowski et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+of+3-%284-Acylaminopiperazin-1-ylalkyl%29indoles+as+Potential+Antihypertensive+Agents%2C"'>Synthesis of 3-(4-Acylaminopiperazin-1-ylalkyl)indoles as Potential Antihypertensive Agents,</a>" J. Med. Chem., vol. 20, No. 11, pp. 148-152, 1977.</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Glamkowski et al., Synthesis of 3 (4 Acylaminopiperazin 1 ylalkyl)indoles as Potential Antihypertensive Agents, J. Med. Chem., vol. 20, No. 11, pp. 148 152, 1977.</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lipp et al., "<a href='http://scholar.google.com/scholar?q="Notiz+uber+einige+Derivate+der+%5B5-Benzyloxy-indolyl-%283%29%5D-glyoxylsaure%2C"'>Notiz uber einige Derivate der [5-Benzyloxy-indolyl-(3)]-glyoxylsaure,</a>" Chem. Ber., vol. 91, pp. 242-243, 1957.</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Lipp et al., Notiz uber einige Derivate der 5 Benzyloxy indolyl (3) glyoxylsaure, Chem. Ber., vol. 91, pp. 242 243, 1957.</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6251923">US6251923</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 28, 1999</td><td class="patent-data-table-td patent-date-value">Jun 26, 2001</td><td class="patent-data-table-td ">Arzneimittelwerk Dresden Gmbh</td><td class="patent-data-table-td ">Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6432987">US6432987</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 15, 2000</td><td class="patent-data-table-td patent-date-value">Aug 13, 2002</td><td class="patent-data-table-td ">Zentaris Ag</td><td class="patent-data-table-td ">Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6545025">US6545025</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 21, 2002</td><td class="patent-data-table-td patent-date-value">Apr 8, 2003</td><td class="patent-data-table-td ">Arzneimittelwerk Dresden Gmbh</td><td class="patent-data-table-td ">Antiinflammatroy agents; antiallergens</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6602890">US6602890</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 21, 2002</td><td class="patent-data-table-td patent-date-value">Aug 5, 2003</td><td class="patent-data-table-td ">Arzneimittelwerk Dresden Gmbh</td><td class="patent-data-table-td ">N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5 -hydroxyindol-3-yl)-2-oxoacetamide, for example; treating eosinophil-related conditions, including chronic obstructive pulmonary disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6613794">US6613794</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 20, 2003</td><td class="patent-data-table-td patent-date-value">Sep 2, 2003</td><td class="patent-data-table-td ">Arzneimittelwerk Dresden Gmbh</td><td class="patent-data-table-td ">Inhibiting tumor necrosis factor alpha, treating eosinophil-related condition, treating inflammatory airway disorder</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6693119">US6693119</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 27, 2000</td><td class="patent-data-table-td patent-date-value">Feb 17, 2004</td><td class="patent-data-table-td ">Baxter Healthcare Sa</td><td class="patent-data-table-td ">Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6903104">US6903104</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 2002</td><td class="patent-data-table-td patent-date-value">Jun 7, 2005</td><td class="patent-data-table-td ">National Health Research Institutes</td><td class="patent-data-table-td ">Antitumor agents, anticarcinogenic agents, a 3-oxoacetamideindolyl compounds, for treating cancer, cytotoxic, and angiogensis inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6919344">US6919344</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 1, 2003</td><td class="patent-data-table-td patent-date-value">Jul 19, 2005</td><td class="patent-data-table-td ">Asta Medica, Aktiengesellschaft</td><td class="patent-data-table-td ">Heterocyclic amines such as N-(Pyridin-4-yl)-(1-(4-fluoro-benzyl)indol-3-yl)glyoxylamide, used for prophylaxis of skin disorders, rheumatic diseases or arthritis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6958348">US6958348</a></td><td class="patent-data-table-td patent-date-value">Aug 29, 2002</td><td class="patent-data-table-td patent-date-value">Oct 25, 2005</td><td class="patent-data-table-td ">Synta Pharmaceuticals Corp.</td><td class="patent-data-table-td ">Side effect reduction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7122674">US7122674</a></td><td class="patent-data-table-td patent-date-value">Jul 31, 2003</td><td class="patent-data-table-td patent-date-value">Oct 17, 2006</td><td class="patent-data-table-td ">Elbion Ag</td><td class="patent-data-table-td ">Process for preparing high-purity hydroxyindolylglyoxylamides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7161009">US7161009</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 21, 2002</td><td class="patent-data-table-td patent-date-value">Jan 9, 2007</td><td class="patent-data-table-td ">Elbion Ag</td><td class="patent-data-table-td ">Antiinflammatory agents; skin disorders; central nervous system disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7166637">US7166637</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2003</td><td class="patent-data-table-td patent-date-value">Jan 23, 2007</td><td class="patent-data-table-td ">Elbion Ag</td><td class="patent-data-table-td ">Hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7211583">US7211583</a></td><td class="patent-data-table-td patent-date-value">Apr 16, 2004</td><td class="patent-data-table-td patent-date-value">May 1, 2007</td><td class="patent-data-table-td ">Elbion Ag</td><td class="patent-data-table-td ">Substituted azaindole as drugs and enzyme inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7365081">US7365081</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 20, 2001</td><td class="patent-data-table-td patent-date-value">Apr 29, 2008</td><td class="patent-data-table-td ">Aeterna Zentaris Gmbh</td><td class="patent-data-table-td ">Antitumor agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7396838">US7396838</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 2005</td><td class="patent-data-table-td patent-date-value">Jul 8, 2008</td><td class="patent-data-table-td ">National Health Research Institutes</td><td class="patent-data-table-td ">antitumor, anticarcinogenic agents; cytotoxic activity and angiogensis inhibitors; leukemia, colorectal cancer; orally</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7452910">US7452910</a></td><td class="patent-data-table-td patent-date-value">Oct 17, 2003</td><td class="patent-data-table-td patent-date-value">Nov 18, 2008</td><td class="patent-data-table-td ">Ziopharm Oncology, Inc.</td><td class="patent-data-table-td ">Reducing side effects, lowering neurotoxicity; longer lasting antitumor action</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7579365">US7579365</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 4, 2002</td><td class="patent-data-table-td patent-date-value">Aug 25, 2009</td><td class="patent-data-table-td ">Ziophram Oncology, Inc.</td><td class="patent-data-table-td ">For therapy of oncoses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7598380">US7598380</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2006</td><td class="patent-data-table-td patent-date-value">Oct 6, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Method of preparation of azaindole derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7662834">US7662834</a></td><td class="patent-data-table-td patent-date-value">Jun 3, 2008</td><td class="patent-data-table-td patent-date-value">Feb 16, 2010</td><td class="patent-data-table-td ">National Health Research Institutes</td><td class="patent-data-table-td ">Methods of 1H-indol-3-yl-2-oxoacetamide compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7807671">US7807671</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2007</td><td class="patent-data-table-td patent-date-value">Oct 5, 2010</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">viricides such as 1-(7-bromo-4-fluoro-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-(4-(1-phenyl-1H-tetrazol-5-yl)piperazin-1-yl)ethane-1,2-dione , used for the treatment of HIV and AIDS</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7807676">US7807676</a></td><td class="patent-data-table-td patent-date-value">Oct 23, 2007</td><td class="patent-data-table-td patent-date-value">Oct 5, 2010</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">1-(4-fluoro-7-(3-methyl-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-(4-(1-phenyl-1H-tetrazol-5-yl)piperazin-1-yl)ethane-1,2-dione; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS; immunomodulators; with AIDS antiviral, antiinfective agent, HIV entry inhibitor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7820820">US7820820</a></td><td class="patent-data-table-td patent-date-value">Aug 24, 2009</td><td class="patent-data-table-td patent-date-value">Oct 26, 2010</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Method of preparation of azaindole derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7829711">US7829711</a></td><td class="patent-data-table-td patent-date-value">May 19, 2009</td><td class="patent-data-table-td patent-date-value">Nov 9, 2010</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">treating HIV or AIDS; viral diseases; purity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7851476">US7851476</a></td><td class="patent-data-table-td patent-date-value">Dec 11, 2006</td><td class="patent-data-table-td patent-date-value">Dec 14, 2010</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7947705">US7947705</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 6, 2007</td><td class="patent-data-table-td patent-date-value">May 24, 2011</td><td class="patent-data-table-td ">Biotie Therapies Gmbh</td><td class="patent-data-table-td ">7-azaindoles and the use thereof as therapeutic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7989453">US7989453</a></td><td class="patent-data-table-td patent-date-value">Dec 20, 2007</td><td class="patent-data-table-td patent-date-value">Aug 2, 2011</td><td class="patent-data-table-td ">Aeterna Zentaris Gmbh</td><td class="patent-data-table-td ">Antitumor agents; for example, N-(2-methyl-6-quinolyl)-[1-(4-chlorobenzyl)indole-3-yl]glyoxylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8008324">US8008324</a></td><td class="patent-data-table-td patent-date-value">Mar 6, 2008</td><td class="patent-data-table-td patent-date-value">Aug 30, 2011</td><td class="patent-data-table-td ">Aeterna Zentaris Gmbh</td><td class="patent-data-table-td ">Antitumor agents; N-propargyl-N-(2-methyl-6-quinolyl)-[1-(4-chlorobenzyl)indol-3-yl]glyoxylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8039486">US8039486</a></td><td class="patent-data-table-td patent-date-value">Feb 8, 2008</td><td class="patent-data-table-td patent-date-value">Oct 18, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8242149">US8242149</a></td><td class="patent-data-table-td patent-date-value">Mar 13, 2006</td><td class="patent-data-table-td patent-date-value">Aug 14, 2012</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Modulators of ATP-binding cassette transporters</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/USRE38624">USRE38624</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 19, 2002</td><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td ">Elbion Ag</td><td class="patent-data-table-td ">Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2363128A2?cl=en">EP2363128A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 13, 2006</td><td class="patent-data-table-td patent-date-value">Sep 7, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Indole modulators of ATP-binding cassette transporters</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004013127A1?cl=en">WO2004013127A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 31, 2003</td><td class="patent-data-table-td patent-date-value">Feb 12, 2004</td><td class="patent-data-table-td ">Elbion Ag</td><td class="patent-data-table-td ">Method for producing highly pure hydroxy indolyl glyoxylic acid amides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004045607A1?cl=en">WO2004045607A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 14, 2003</td><td class="patent-data-table-td patent-date-value">Jun 3, 2004</td><td class="patent-data-table-td ">Ute Egerland</td><td class="patent-data-table-td ">Novel hydroxyindoles, use as inhibitors of phosphodiesterase 4 and method for production thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005004801A2?cl=en">WO2005004801A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 22, 2004</td><td class="patent-data-table-td patent-date-value">Jan 20, 2005</td><td class="patent-data-table-td ">Thomas Stephen Coulter</td><td class="patent-data-table-td ">Indole, azaindole and related heterocyclic n-substituted piperazine derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006099256A2?cl=en">WO2006099256A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 13, 2006</td><td class="patent-data-table-td patent-date-value">Sep 21, 2006</td><td class="patent-data-table-td ">Vertex Pharma</td><td class="patent-data-table-td ">Modulators of atp-binding cassette transporters</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S314000">514/314</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S419000">514/419</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc546/defs546.htm&usg=AFQjCNEVbqUa3Y2xdPcpKajVJNycCal0yg#C546S168000">546/168</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc548/defs548.htm&usg=AFQjCNEJR3l-3fNtZ4E4S53vEr85bVXOrQ#C548S493000">548/493</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc546/defs546.htm&usg=AFQjCNEVbqUa3Y2xdPcpKajVJNycCal0yg#C546S278100">546/278.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S339000">514/339</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc548/defs548.htm&usg=AFQjCNEJR3l-3fNtZ4E4S53vEr85bVXOrQ#C548S491000">548/491</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0043000000">A61P43/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031404000">A61K31/404</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0037000000">A61P37/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0401120000">C07D401/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031496000">A61K31/496</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031000000">A61K31/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031440000">A61K31/44</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0209180000">C07D209/18</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031443900">A61K31/4439</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031446500">A61K31/4465</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031445000">A61K31/445</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031400000">A61K31/40</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031454000">A61K31/454</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031452300">A61K31/4523</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0037020000">A61P37/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0011000000">A61P11/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031442700">A61K31/4427</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0037060000">A61P37/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0401060000">C07D401/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0029000000">A61P29/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0037080000">A61P37/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0011060000">A61P11/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0401140000">C07D401/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031403000">A61K31/403</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0209240000">C07D209/24</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0209220000">C07D209/22</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07D401/14">C07D401/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07D401/12">C07D401/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07D209/22">C07D209/22</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=JJJNBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07D401/06">C07D401/06</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07D209/22</span>, <span class="nested-value">C07D401/06</span>, <span class="nested-value">C07D401/14</span>, <span class="nested-value">C07D401/12</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Jun 28, 2011</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 9, 2010</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 3, 2009</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIM 1 IS DETERMINED TO BE PATENTABLE AS AMENDED. NEW CLAIMS 12-14 ARE ADDED AND DETERMINED TO BE PATENTABLE. CLAIMS 2-11 WERE NOT REEXAMINED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 13, 2008</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20080226</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 20, 2007</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BAXTER HEALTHCARE S.A., SWITZERLAND</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BAXTER INTERNATIONAL INC., ILLINOIS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTA MEDICA AKTIENGESELLSCHAFT;REEL/FRAME:019714/0687</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20011105</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ZIOPHARM ONCOLOGY, INC., MASSACHUSETTS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAXTER HEALTHCARE S.A.;BAXTER INTERNATIONAL, INC.;REEL/FRAME:019714/0701</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20070725</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 28, 2007</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 5, 2003</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 28, 2001</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 2, 1998</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ASTA MEDICA AKTIENGESELLSCHAFT, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEBAUT, GUILLAUME;MENCIU, CECILIA;KUTSCHER, BERNHARD;ANDOTHERS;REEL/FRAME:009032/0659;SIGNING DATES FROM 19971006 TO 19971014</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U3QrRn1060T-6O1oAAcTZ9zmKJoMA\u0026id=JJJNBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U2lmaxX9-iA_gXVPkaGPUmMAyTrWw\u0026id=JJJNBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U0n4MDuL9LnYFSCI_ZuwgB0x1V7sg","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Antiallergens_antihistamines_immunosuppr.pdf?id=JJJNBAABERAJ\u0026output=pdf\u0026sig=ACfU3U3XTX4zPGB8aZMsFvHnFTYhFj51kg"},"sample_url":"http://www.google.com/patents/reader?id=JJJNBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>